|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mazzanti R, Gramantieri L and Bolondi L:
Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol
Aspects Med. 29:130–143. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Epidemiology of
hepatocellular carcinoma in USA. Hepatol Res. 37 (Suppl 2):S88–S94.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greten TF, Duffy AG and Korangy F:
Hepatocellular Carcinoma from an immunologic perspective. Clin
Cancer Res. 19:6678–6685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boles KS, Vermi W, Facchetti F, Fuchs A,
Wilson TJ, Diacovo TG, Cella M and Colonna M: A novel molecular
interaction for the adhesion of follicular CD4 T cells to
follicular DC. Eur J Immunol. 39:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He W, Zhang H, Han F, Chen X, Lin R, Wang
W, Qiu H, Zhuang Z, Liao Q, Zhang W, et al: CD155T/TIGIT signaling
regulates CD8(+) T-cell metabolism and promotes tumor progression
in human gastric cancer. Cancer Res. 77:6375–6388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joller N, Hafler JP, Brynedal B, Kassam N,
Spoerl S, Levin SD, Sharpe AH and Kuchroo VK: Cutting Edge: TIGIT
Has T cell-intrinsic inhibitory functions. J Immunol.
186:1338–1342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu X, Harden K, Gonzalez LC, Francesco M,
Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The
surface protein TIGIT suppresses T cell activation by promoting the
generation of mature immunoregulatory dendritic cells. Nat Immunol.
10:48–57. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levin SD, Taft DW, Brandt CS, Bucher C,
Howard ED, Chadwick EM, Johnston J, Hammond A, Bontadelli K,
Ardourel D, et al: Vstm3 is a member of the CD28 family and an
important modulator of T-cell function. Eur J Immunol. 41:902–915.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joller N, Lozano E, Burkett PR, Patel B,
Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al: Treg cells
expressing the coinhibitory molecule TIGIT selectively inhibit
proinflammatory Th1 and Th17 cell responses. Immunity. 40:569–581.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kurtulus S, Sakuishi K, Ngiow SF, Joller
N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK and Anderson AC: TIGIT
predominantly regulates the immune response via regulatory T cells.
J Clin Invest. 125:4053–4062. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trehanpati N and Vyas AK: Immune
regulation by T regulatory cells in hepatitis B virus-related
inflammation and cancer. Scand J Immunol. 85:175–181. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurose K, Ohue Y, Sato E, Yamauchi A,
Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M and Nakayama E:
Increase in activated treg in til in lung cancer and in vitro
depletion of treg by ADCC using an antihuman CCR4 mAb (KM2760). J
Thorac Oncol. 10:74–83. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Godefroy E, Zhong H, Pham P, Friedman D
and Yazdanbakhsh K: TIGIT-positive circulating follicular helper T
cells display robust B-cell help functions: Potential role in
sickle cell alloimmunization. Haematologica. 100:1415–1425. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goding SR, Wilson KA, Xie Y, Harris KM,
Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE and Antony PA:
Restoring immune function of tumor-specific CD4+ T cells during
recurrence of melanoma. J Immunol. 190:4899–4909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stengel KF, Harden-Bowles K, Yu X, Rouge
L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL and Grogan
JL: Structure of TIGIT immunoreceptor bound to poliovirus receptor
reveals a cell-cell adhesion and signaling mechanism that requires
cis-trans receptor clustering. Proc Natl Acad Sci USA.
109:5399–5404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stanietsky N, Simic H, Arapovic J, Toporik
A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al:
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell
cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao W, Dong Y, Wu C, Ma Y, Jin Y and Ji
Y: TIGIT overexpression diminishes the function of CD4 T cells and
ameliorates the severity of rheumatoid arthritis in mouse models.
Exp Cell Res. 340:132–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chauvin JM, Pagliano O, Fourcade J, Sun Z,
Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ and
Zarour HM: TIGIT and PD-1 impair tumor antigen-specific CD8(+) T
cells in melanoma patients. J Clin Invest. 125:2046–2058. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song Y, Wang B, Song R, Hao Y, Wang D, Li
Y, Jiang Y, Xu L, Ma Y, Zheng H, et al: T-cell Immunoglobulin and
ITIM Domain Contributes to CD8(+) T-cell Immunosenescence. Aging
Cell. 17:2018. View Article : Google Scholar
|
|
24
|
Imbeaud S, Ladeiro Y and Zucman-Rossi J:
Identification of novel oncogenes and tumor suppressors in
hepatocellular carcinoma. Semin Liver Dis. 30:75–86. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matsuzaki K, Murata M, Yoshida K, Sekimoto
G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M,
Fujisawa J, et al: Chronic inflammation associated with hepatitis C
virus infection perturbs hepatic transforming growth factor beta
signaling, promoting cirrhosis and hepatocellular carcinoma.
Hepatology. 46:48–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang L and Karin M: Roles of tumor
suppressors in regulating tumor-associated inflammation. Cell Death
Differ. 21:1677–1686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanz-Cameno P, Trapero-Marugán M, Chaparro
M, Jones EA and Moreno-Otero R: Angiogenesis: From chronic liver
inflammation to hepatocellular carcinoma. J Oncol. 2010:2721702010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pedroza-Gonzalez A, Zhou G, Vargas-Mendez
E, Boor PP, Mancham S, Verhoef C, Polak WG, Grünhagen D, Pan Q,
Janssen H, et al: Tumor-infiltrating plasmacytoid dendritic cells
promote immunosuppression by Tr1 cells in human liver tumors.
Oncoimmunology. 4:e10083552015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Callahan MK, Postow MA and Wolchok JD:
CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front
Oncol. 4:3852014.PubMed/NCBI
|
|
30
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stanietsky N, Rovis TL, Glasner A, Seidel
E, Tsukerman P, Yamin R, Enk J, Jonjic S and Mandelboim O: Mouse
TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur
J Immunol. 43:2138–2150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Johnston RJ, Comps-Agrar L, Hackney J, Yu
X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al:
The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T
cell effector function. Cancer Cell. 26:923–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jenne CN and Kubes P: Immune surveillance
by the liver. Nat Immunol. 14:996–1006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nemeth E, Baird AW and O'Farrelly C:
Microanatomy of the liver immune system. Semin Immunopathol.
31:333–343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong Z, Carroll KD, Policarpio D, Osborn
C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K,
et al: Anti-transforming growth factor beta receptor II antibody
has therapeutic efficacy against primary tumor growth and
metastasis through multieffects on cancer, stroma, and immune
cells. Clin Cancer Res. 16:1191–1205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zakrzewski PK, Cygankiewicz AI,
Mokrosiński J, Nowacka-Zawisza M, Semczuk A, Rechberger T and
Krajewska WM: Expression of endoglin in primary endometrial cancer.
Oncology. 81:243–250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mao L, Hou H, Wu S, Zhou Y, Wang J, Yu J,
Wu X, Lu Y, Mao L, Bosco MJ, et al: TIGIT signalling pathway
negatively regulates CD4+ T-cell responses in systemic
lupus erythematosus. Immunology. 151:280–290. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lowther DE, Goods BA, Lucca LE, Lerner BA,
Raddassi K, van Dijk D, Hernandez AL, Duan X, Gunel M, Coric V, et
al: PD-1 marks dysfunctional regulatory T cells in malignant
gliomas. JCI Insight. 1(pii): e859352016.PubMed/NCBI
|
